Filtered By:
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 1360 results found since Jan 2013.

Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke Stroke
Conclusions Hospitals often overestimate their ability to deliver timely tPA to treated patients. Our findings indicate the need to routinely provide comparative provider performance rates as a key step to improving the quality of acute stroke care.
Source: JAHA:Journal of the American Heart Association - July 22, 2015 Category: Cardiology Authors: Lin, C. B., Cox, M., Olson, D. M., Britz, G. W., Constable, M., Fonarow, G. C., Schwamm, L., Peterson, E. D., Shah, B. R. Tags: Stroke Source Type: research

Accuracy of First Recorded “Last Known Normal” Times of Stroke Code Patients
This study investigates whether a difference exists between preliminary LKN times (first responders and emergency department practitioners) and revised LKN times (neurology/stroke practitioners), and what potential impact on emergent management of acute stroke this discrepancy may pose.
Source: Journal of Stroke and Cerebrovascular Diseases - September 1, 2015 Category: Neurology Authors: Ilana Spokoyny, Rema Raman, Karin Ernstrom, Alex J. Kim, Brett C. Meyer, Navaz P. Karanjia Source Type: research

Rapidly improving neurological deficit of stroke; case series in Academic institute, KAUH, Jeddah (P4.283)
Conclusions:Rapidly improving patient represent a challenge to whether tPA should be given. However, the good outcome with thrombolytic therapy observed in our study, will hopfuly support the decision to treat.Study Supported by: nonDisclosure: Dr. khoja has nothing to disclose. Dr. Alshaer has nothing to disclose. Dr. al-Turkistani has nothing to disclose. Dr. Al-Mekhalfi has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: khoja, a., Al-Shaer, D., al-Turkistani, a., Al-Mekhalfi, M. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research

Thrombolytic Therapy of Acute Ischemic Stroke during Early Pregnancy
Thrombolytic treatment (recombinant tissue plasminogen activator [rt-PA]) has established efficacy in acute ischemic stroke, but pregnancy has been an exclusion criterion for all clinical trials that validated alteplase in acute stroke, so our knowledge about its use in this condition is limited.Herein we report the successful use of intravenous rt-PA thrombolysis, uncomplicated by neither hemorrhage development nor other complication in a woman who was 13 weeks pregnant with acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - November 28, 2017 Category: Neurology Authors: Anne Landais, Hugo Chaumont, Rachel Dellis Tags: Case Studies Source Type: research

Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review
Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab.
Source: Journal of Stroke and Cerebrovascular Diseases - March 16, 2018 Category: Neurology Authors: Yuichiro Ohya, Noriko Makihara, Kayo Wakisaka, Takao Morita, Tetsuro Ago, Takanari Kitazono, Hitonori Takaba Tags: Case Studies Source Type: research

Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke
ConclusionsSite specific delivery of platelet rich clots to the MCA origin resulted in high rates of MCA occlusion, low rates of spontaneous clot lysis and large infarction. These platelet rich clots were highly resistant to tPA with or without microbubble-enhanced sonothrombolysis. This resistance of platelet rich clots to enhanced thrombolysis may explain recanalization failures clinically and should be an impetus to better clot-type identification and alternative recanalization methods.
Source: Experimental and Translational Stroke Medicine - January 27, 2015 Category: Neurology Source Type: research

Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan
Background: Asians with atrial fibrillation carry a higher risk of ischemic stroke than non-Asians even under treatment of nonvitamin K antagonist oral anticoagulants. The purpose of the study was to observe the feasibility of intravenous thrombolytic therapy after administering a reversal agent, idarucizumab, in dabigatran-treated patients with acute ischemic stroke in Taiwan. Methods: Dabigatran-treated patients with acute ischemic stroke who received intravenous recombinant tissue plasminogen activator (rt-PA) after idarucizumab reversal were enrolled in the retrospective nationwide study.
Source: Journal of Stroke and Cerebrovascular Diseases - December 17, 2018 Category: Neurology Authors: Chen-Wen Fang, Yi-Te Tsai, Ping-Chen Chou, Hsi-Ming Chen, Chien-Ming Lu, Chen-Rong Tsao, Chih-Lin Chen, Mu-Chien Sun, Yu-Song Shih, Cheng-Yang Hsieh, Lu-An Chen, Po-Lin Chen, Jung-Tze Yeh, Yi-Heng Li Source Type: research

Is Endovascular Therapy for Stroke Cost-Effective Globally? A Systematic Review of the Literature
The standard of care for eligible patients with acute ischemic stroke (AIS) has been thrombolytic therapy with intravenous (IV) tissue plasminogen activator (tPA) within 4.5  h of symptom onset to achieve reperfusion and reduce morbidity and mortality.1-3 However, the emergence of endovascular therapy (EVT) has changed the treatment paradigm for large vessel occlusion (LVO) acute ischemic stroke (AIS). The evidence supporting the use of EVT as first-line treatment for LVO stroke is unequivocal.45
Source: Journal of Stroke and Cerebrovascular Diseases - February 5, 2021 Category: Neurology Authors: Muhammad Waqas, Andrew D. Gong, Bennett R. Levy, Rimal H. Dossani, Kunal Vakharia, Justin M. Cappuzzo, Alexander Becker, Ashish Sonig, Vincent M. Tutino, Faisal Almayman, Jason M. Davies, Kenneth V. Snyder, Adnan H. Siddiqui, Elad I. Levy Source Type: research

Moving from traditional to more advanced treatments in stroke care is cost-effective: A case study from Greece
Ischemic stroke (IS) is one of the leading causes of mortality and disability,1, 2 with the economic burden of post-stroke care being substantial.1, 2 After incidence of IS, the following effective treatments have been found to significantly improve survival and quality of life: (a) treatment in specialized centres (Stroke Units; SU), (b) use of intravenous thrombolytic therapy (IVT), (c) use of endovascular thrombectomy (EVT) for patients with large vessel occlusions (LVO) and (d) rehabilitation.
Source: Journal of Stroke and Cerebrovascular Diseases - September 10, 2022 Category: Neurology Authors: Konstantinos Dimitriadis, Ilias Kyriopoulos, Georgios Tsivgoulis, Konstantinos Vemmos, Wolfgang G. Kunz, Elias Mossialos Source Type: research

Time to ct scan imaging after symptom onset among ischeamic stroke patients presenting to a quaternary hospital in ghana
This study sought to determine the time of onset of symptoms to the time a CT imaging was done among patients presenting with acute stroke at the Korle-Bu Teaching Hospital.
Source: Journal of Stroke and Cerebrovascular Diseases - March 30, 2023 Category: Neurology Authors: F. Duodu, D. Brodie Mends, B. Agbinko-Djobalar, P. Pekyi-Boateng, M. Amerwornu, P Adjei, A Akpalu, K Nkromah Source Type: research

Body temperature, blood infection parameters, and outcome of thrombolysis‐treated ischemic stroke patients
ConclusionA lower level of systemic inflammation at time of thrombolysis may be associated with clinical improvement and good outcome at three‐months. Increase in body temperature during the first 24 h associates with lack of clinical improvement and worse patient outcome.
Source: International Journal of Stroke - April 1, 2013 Category: Neurology Authors: Marjaana Tiainen, Atte Meretoja, Daniel Strbian, Joel Suvanto, Sami Curtze, Perttu J. Lindsberg, Lauri Soinne, Turgut Tatlisumak, Tags: Research Source Type: research

Translational perspectives on perfusion–diffusion mismatch in ischemic stroke
Magnetic resonance imaging has tremendous potential to illuminate ischemic stroke pathophysiology and guide rational treatment decisions. Clinical applications to date have been largely limited to trials. However, recent analyses of the major clinical studies have led to refinements in selection criteria and improved understanding of the potential implications for the risk vs. benefit of thrombolytic therapy. In parallel, preclinical studies have provided complementary information on the evolution of stroke that is difficult to obtain in humans due to the requirement for continuous or repeated imaging and pathological veri...
Source: International Journal of Stroke - October 1, 2013 Category: Neurology Authors: Bruce C. V. Campbell, I. Mhairi Macrae Tags: Review Source Type: research

National Survey of Thrombolytic Therapy for Acute Ischemic Stroke in Taiwan 2003-2010
Data on thrombolytic therapy at the national level is scarce in Asia. Understanding current practice pattern is important for a policy maker in decision making. This cross-sectional study analyzed the utilization pattern of thrombolytic therapy for acute ischemic stroke (AIS) in Taiwan from 2003 through 2010 and identified factors associated with post-therapy intracerebral hemorrhage (ICH) and mortality. From the Taiwan National Health Insurance Research Database, we retrieved inpatient claims for patients with AIS. The frequency of thrombolytic therapy in AIS admissions and its association with the characteristics of pati...
Source: Journal of Stroke and Cerebrovascular Diseases - October 14, 2013 Category: Neurology Authors: Cheng-Yang Hsieh, Chih-Hung Chen, Yi-Chi Chen, Yea-Huei Kao Yang Tags: Original Articles Source Type: research

Predictors of In-hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
This study aimed to determine the independent predictors of in-hospital mortality (IHM) and the risk of sICH after rt-PA therapy. A total of 1007 patients (mean age, 72 ± 12 years; 52% women; mean National Institutes of Health Stroke Scale [NIHSS] score, 11.6 ± 5.6) with AIS treated with rt-PA were enrolled in this study during a 42-month period beginning in November 2007. Univariate and multivariate regression analyses were performed to estimate the predictors of IHM. Eighty-three of the 1007 patients (8.2%) died during hospitalization (mean duration of hospitalization, 10 ± 1.8 days). Logistic regression estimated the...
Source: Journal of Stroke and Cerebrovascular Diseases - May 14, 2012 Category: Neurology Authors: Mohamed Al-Khaled, Christine Matthis, Jürgen Eggers Tags: Original Articles Source Type: research